The head of clinical trials at China National Pharmaceutical Group Corp (Sinopharm) laboratories in Peru, German Malaga, has stated that Peru's clinical trials of Sinopharm's COVID-19 vaccine were temporarily suspended by the Peruvian National Institute of Health after a participant reported a decrease in muscle strength in his legs, CNN reported on Monday.
Malaga told CNN that the 64-year-old patient, with allegedly more than 20 years of badly-controlled diabetes, is in stable condition.
According to CNN, the reason for the symptoms cannot yet be determined and an investigation is ongoing.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes